Overview
Background
Dr Sandra Brosda is a Research Fellow within the Surgical Oncology group led by Professor Andrew Barbour.
Dr Brosda was awarded a PhD in bioinformatics and cancer genetics from the University of Queensland in November 2020. Her research focused on biomarker discovery and intra-tumour heterogeneity and tumour evolution in oesophageal adenocarcinoma (OAC). In 2021, Dr Brosda was awarded a Cure Cancer Australia PdCCRS grant and an MSH project grant to further investigate tumour evolution to improve precision medicine in OAC.
She has been involved in research projects covering genetics, epigenetics, spatial transcriptomics, radiomics, ctDNA and quality of life assessments in the context of cancer. Overall, her research applies bioinformatics tools and approaches to cancer genomics to improve precision medicine and health outcomes for patients with melanoma, oesophago-gastric cancer and pancreatic cancer.
Availability
- Dr Sandra Brosda is:
- Not available for supervision
Fields of research
Qualifications
- Bachelor of Bioinformatics, University of Bielefeld
- Masters (Coursework) of Bioinformatics, University of Bielefeld
- Doctor of Philosophy, The University of Queensland
Research interests
-
Bioinformatics
-
Intra-tumour heterogeneity
-
Tumour evolution
-
Cancer genetics
Works
Search Professor Sandra Brosda’s works on UQ eSpace
Featured
2024
Journal Article
Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy
Brosda, Sandra, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lonie, James M., Belle, Clemence J., Newell, Felicity, Koufariotis, Lambros T., Addala, Venkateswar, Naeini, Marjan M., Simes, John, Walpole, Euan T., Mai, Gang T., Watson, David I., Karapetis, Chris S., Gebski, Val, Barnes, Elizabeth H., Oostendorp, Martijn, Wilson, Kate, Ackland, Stephen P., Shannon, Jenny, Marx, Gavin, Burge, Matthew, Finch, Robert, Thomas, Janine, Varma, Suresh, Nott, Louise, Pearson, John V., Krause, Lutz ... AGITG DOCTOR Investigators (2024). Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy. Genome Medicine, 16 (1) 90, 90. doi: 10.1186/s13073-024-01362-z
2024
Journal Article
Intra‐tumoral and peripheral blood <scp>TIGIT</scp> and <scp>PD</scp>‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma
Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Fennell, Éanna, Hennessy, Aoife, Leahy, Ciara I., Murray, Paul G., Bednarska, Karolina, Brosda, Sandra, Trotman, Judith, Berkahn, Leanne, Zaharia, Andreea, Birch, Simone, Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Snell, Cameron, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Shanavas, Mohamed, Blyth, Emily, Steidl, Christian, Savage, Kerry, Farinha, Pedro ... Gandhi, Maher K. (2024). Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma. American Journal of Hematology, 99 (11), 2096-2107. doi: 10.1002/ajh.27459
2023
Journal Article
Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma
Belle, Clemence J., Lonie, James M., Brosda, Sandra and Barbour, Andrew P. (2023). Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma. Frontiers in Immunology, 14 1330635, 1-8. doi: 10.3389/fimmu.2023.1330635
2023
Journal Article
The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank
Lonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo and Barbour, Andrew P. (2023). The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank. Frontiers in Immunology, 14 1220129, 1-15. doi: 10.3389/fimmu.2023.1220129
2023
Journal Article
ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients
Aoude, Lauren G., Brosda, Sandra, Ng, Jessica, Lonie, James M., Belle, Clemence J., Patel, Kalpana, Koufariotis, Lambros T., Wood, Scott, Atkinson, Victoria, Smithers, B. Mark, Pearson, John V., Waddell, Nicola, Barbour, Andrew P. and Bonazzi, Vanessa F. (2023). ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients. Journal of Molecular Diagnostics, 25 (10), 771-781. doi: 10.1016/j.jmoldx.2023.06.014
2023
Journal Article
C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients
Bonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology. doi: 10.1111/ajco.13993
2023
Journal Article
Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
M. Naeini, Marjan, Newell, Felicity, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lampe, Guy, Koufariotis, Lambros T., Lakis, Vanessa, Addala, Venkateswar, Kondrashova, Olga, Johnston, Rebecca L., Sharma, Sowmya, Brosda, Sandra, Holmes, Oliver, Leonard, Conrad, Wood, Scott, Xu, Qinying, Thomas, Janine, Walpole, Euan, Tao Mai, G., Ackland, Stephen P., Martin, Jarad, Burge, Matthew, Finch, Robert, Karapetis, Christos S., Shannon, Jenny, Nott, Louise, Bohmer, Robert, Wilson, Kate ... Waddell, Nicola (2023). Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications, 14 (1) 3155, 3155. doi: 10.1038/s41467-023-38891-x
2022
Conference Publication
Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma
Gunawardana, Jay, Law, Soi C., Sabdia, Muhammed B., Bednarska, Karolina, Brosda, Sandra, Zaharia, Andreea, Tsang, Hennes, de Long, Lilia M., Burgess, Melinda, Talaulikar, Dipti, Lee, Justina N., Jude, Emily, Hawkes, Eliza A., Jain, Sanjiv, Nath, Karthik, Gould, Clare, Swain, Fiona, Tobin, Joshua W. D., Keane, Colm, Birch, Simone, Shanavas, Mohamed, Snell, Cameron and Gandhi, Maher K. (2022). Abstract A17: the immune checkpoints TIGIT and PD-1 are markedly upregulated in NLPHL compared to classical Hodgkin Lymphoma. Third AACR International Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application, 23-25 June 2022, Boston, MA USA. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/2643-3249.lymphoma22-a17
2022
Conference Publication
Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma
Aoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357
2022
Conference Publication
Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistry
Sharma, Sowmya, Naeini, Marjan, Aoude, Lauren G., Bonazzi, Vanessa F., Gartside, Michael G., Loffler, Kelly A., Patel, Kalpana, Newell, Felicity, Lampe, Guy, Brosda, Sandra, Thomas, Janine, Smithers, Mark, Simes, John, Watson, David I., Pearson, John, Barbour, Andrew and Waddell, Nic (2022). Classification of esophageal adenocarcinoma into subgroups that are associated with patient survival using RNA-seq and immunohistochemistry. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2022
Journal Article
Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage
Molendijk, Jeffrey, Kolka, Cathryn M., Cairns, Henry, Brosda, Sandra, Mohamed, Ahmed, Shah, Alok K., Brown, Ian, Hodson, Mark P., Hennessy, Thomas, Liu, Guanghao, Stoll, Thomas, Richards, Renee S., Gartside, Michael, Patel, Kalpana, Clemons, Nicholas J., Phillips, Wayne A., Barbour, Andrew, Westerhuis, Johan A. and Hill, Michelle M. (2022). Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid‐induced DNA damage. Clinical and Translational Medicine, 12 (5) e810, 1-19. doi: 10.1002/ctm2.810
2022
Journal Article
ctDNA as a biomarker of progression in oesophageal adenocarcinoma
Bonazzi, V. F., Aoude, L. G., Brosda, S., Lonie, J. M., Patel, K., Bradford, J. J., Koufariotis, L. T., Wood, S., Smithers, B. Mark, Waddell, N. and Barbour, A. P. (2022). ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open, 7 (3) 100452, 100452. doi: 10.1016/j.esmoop.2022.100452
2022
Journal Article
C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett’s esophagus and esophageal adenocarcinoma
Kolka, Cathryn M., Webster, Julie, Lepletier, Ailin, Winterford, Clay, Brown, Ian, Richards, Renee S., Zelek, Wioleta M., Cao, Yilang, Khamis, Ramlah, Shanmugasundaram, Karthik B., Wuethrich, Alain, Trau, Matt, Brosda, Sandra, Barbour, Andrew, Shah, Alok K., Eslick, Guy D., Clemons, Nicholas J., Morgan, B. Paul and Hill, Michelle M. (2022). C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett’s esophagus and esophageal adenocarcinoma. Frontiers in Immunology, 13 842023. doi: 10.3389/fimmu.2022.842023
2021
Journal Article
Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients
Aoude, Lauren G., Wong, Bernadette, Bonazzi, Vanessa F, Brosda, Sandra, Walters, Shaun B., Koufariotis, Lambros T., Naeini, Marjan M., Pearson, John V, Oey, Harald, Patel, Kalpana, Bradford, Julia J., Bloxham, Conor J, Atkinson, Victoria, Law, Phillip, Strutton, Geoffrey, Bayley, Gerard, Yang, Samuel, Smithers, B. Mark, Waddell, Nicola, Miles, Kenneth and Barbour, Andrew P. (2021). Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients. Molecular Cancer Research, 19 (6) molcanres.1038.2020, 950-956. doi: 10.1158/1541-7786.mcr-20-1038
2021
Journal Article
EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity
Gandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520
2021
Journal Article
Complications and survival after hybrid and fully minimally invasive oesophagectomy
Veenstra, M. M. K., Smithers, B. M., Visser, E., Edholm, D., Brosda, S., Thomas, J. M., Gotley, D. C., Thomson, I. G., Wijnhoven, B. P. L. and Barbour, A. P. (2021). Complications and survival after hybrid and fully minimally invasive oesophagectomy. BJS Open, 5 (1) zraa033, 1-7. doi: 10.1093/bjsopen/zraa033
2020
Other Outputs
Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma
Brosda, Sandra (2020). Spatial and temporal tumour evolution and genetic biomarker discovery for personalised treatment in oesophageal adenocarcinoma. PhD Thesis, Medicine Faculty, The University of Queensland. doi: 10.14264/89e3f4f
2020
Journal Article
Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
Aoude, Lauren G., Bonazzi, Vanessa F., Brosda, Sandra, Patel, Kalpana, Koufariotis, Lambros T., Oey, Harald, Nones, Katia, Wood, Scott, Pearson, John V., Lonie, James M., Arneil, Melissa, Atkinson, Victoria, Smithers, B. Mark, Waddell, Nicola and Barbour, Andrew P. (2020). Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. Scientific Reports, 10 (1) 17687, 17687. doi: 10.1038/s41598-020-74956-3
2020
Journal Article
Impact of fruit orientation and pelleting material on water uptake and germination performance in artificial substrate for sugar beet
Blunk, Sebastian, Hoffer, Jeroen, Brosda, Sandra, de Heer, Martine I., Sturrock, Craig J. and Mooney, Sacha J. (2020). Impact of fruit orientation and pelleting material on water uptake and germination performance in artificial substrate for sugar beet. PLoS ONE, 15 (5) e0232875, e0232875. doi: 10.1371/journal.pone.0232875
2019
Journal Article
Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy
van Hootegem, S. J. M., Smithers, B. M., Gotley, D. C., Brosda, S., Thomson, I. G., Thomas, J. M., Gartside, M. and Barbour, A. P. (2019). Baseline neutrophil–lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. Diseases of the Esophagus, 33 (6). doi: 10.1093/dote/doz082
Supervision
Availability
- Dr Sandra Brosda is:
- Not available for supervision
Supervision history
Current supervision
-
Doctor Philosophy
Deep spatial phenotyping analysis to characterize cancer evolution
Principal Advisor
Other advisors: Professor Andrew Barbour
-
Doctor Philosophy
Haressing tumour immune responses in oesophageal cancer: towards better personalised therapeutic strategies
Associate Advisor
Other advisors: Professor Andrew Barbour
Media
Enquiries
For media enquiries about Dr Sandra Brosda's areas of expertise, story ideas and help finding experts, contact our Media team: